As CRISPR–Cas adoption soars, summit calls for genome editing oversight
By Eric Smalley,
Nature Biotechnology
| 06. 06. 2018
Researchers are using a pair of initiatives, launched within a few days of each other, to widen the discussion about genome editing oversight to include countries often excluded from the conversation. At a meeting in Paris on March 23, a group of European biotech researchers launched the Association for Responsible Research and Innovation in Genome Editing (ARRIGE). Two days earlier, Nature published a call by two science, technology and society scholars to establish a global gene editing observatory (Nature 555, 435–437, 2018). The initiatives...
Related Articles
By Mariella Bodemeier Loayza Careaga, The Scientist | 03.15.2024
Scientists have genetically modified isolated microbes for decades. Now, using CRISPR, they intend to target entire microbiomes.
Humans are never alone. Even in a room devoid of other people, they are always in the company of billions of microscopic beings...
By Gerry Smith, Bloomberg | 03.12.2024
When Celenise Mahmood first learned about two new gene therapies that could cure sickle cell disease, she felt a wave of relief.
Her 9-year-old son, Navid, has the inherited blood disorder. By age 5, he’d had over 30 life-saving blood...
By Carol Cardona and Michelle Kromm, Scientific American | 03.11.2024
By Nada Hassanein, New Jersey Monitor | 03.14.2024
The U.S. Food and Drug Administration late last year approved two breakthrough gene therapies for sickle cell disease patients. Now a new federal program seeks to make these life-changing treatments available to patients with low incomes — and it could...